Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few

Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.

STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few

In Minnesota, a boy named Yannick learns he shares the same rare disease, Duchenne muscular dystrophy, with another boy named Brecken. Despite their similar conditions, the two friends bond over their shared smiles and love for creating virtual worlds on Minecraft. While they rarely discuss their condition, their mothers frequently compare their progress, noticing that Brecken's condition appears to be improving while Yannick's worsens.

Last winter, Brecken began receiving an experimental drug created by Avidity Biosciences, which helps the body's protein-making system bypass a specific gene linked to Duchenne. This innovative approach has shown promising results in clinical trials, potentially halting the disease's progression in some patients. However, the cost of such targeted therapies limits access for most individuals.

While the "skipping" strategies could potentially benefit around 70% of the 10,000 to 15,000 U.S. boys and men affected by Duchenne muscular dystrophy, only about 7% of patients - around 900 Americans - are eligible for Avidity's drug, Del-zota. Currently, the drug is under Food and Drug Administration review, making it difficult for many patients to access this promising treatment.

Rewritten by urgent.news; may contain errors — check the original.

Read the original at statnews.com →

Report a problem with this story

More in Health & Medicine

More from Wednesday 7 October →